Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 6/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | CPN1 | P15169 | 1/20 | 0.36 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18361920 | 0.82 | CPN1 (0.39) | SLC6A2SLC6A4SLC6A3OPRD1CPN1 | |
| SCHEMBL18469989 | 0.74 | CPN1 (0.38) | SLC6A2SLC6A4SLC6A3OPRD1CPN1 | |
| SCHEMBL27293691 | 0.71 | OPRD1 (0.33) | OPRD1CPN1CPB2 | |
| SCHEMBL5649063 | 0.69 | SLC6A2 (0.34) | SLC6A2SLC6A4CPN1CPB2 | |
| SCHEMBL10158896 | 0.69 | TSHR (0.43) | CHRNB2CHRNA4 | |
| SCHEMBL23562953 | 0.69 | CHRNB2 (0.36) | SLC6A4CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL14748516 | 0.69 | ALOX15 (0.37) | SLC6A2SLC6A4SLC6A3OPRD1CPN1 | |
| SCHEMBL28771692 | 0.68 | CPN1 (0.41) | SLC6A2SLC6A4SLC6A3OPRD1CPN1 | |
| SCHEMBL11446825 | 0.68 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3CPN1CPB2 | |
| Trifluoroacetic Acid SCHEMBL18428957 | 0.67 | OPRD1 (0.35) | SLC6A2SLC6A4OPRD1CPN1CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130060013-A1 | Compounds useful for treating neurodegenerative disorders | SATORI PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130060013-A1 | Compounds useful for treating neurodegenerative disorders | SNCA, HTT, CLN6 | SLC6A2 42/4885SLC6A4 93/4885SLC6A3 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.